Premium
Boosting regulatory T‐cell function with the humanized CD4‐specific humanized monoclonal antibody Tregalizumab (BT‐061)
Author(s) -
HumbletBaron Stéphanie,
Baron Frédéric
Publication year - 2015
Publication title -
immunology and cell biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.999
H-Index - 104
eISSN - 1440-1711
pISSN - 0818-9641
DOI - 10.1038/icb.2014.120
Subject(s) - foxp3 , immunology , autoimmunity , il 2 receptor , regulatory t cell , medicine , humanized mouse , immune system , t cell , transplantation , enteropathy , biology , disease
Regulatory T cells (Tregs) represent a subset of CD4+ T cells that express the forkhead box protein 3 factor (FOXP3) in their nuclei1 and the high-affinity interleukin 2 (IL-2) receptor CD25 on their cell surface as they are dependent on IL-2 for their homeostasis.2 Since their discovery 20 years ago,3 Tregs have proven to be indispensable for maintaining immunological self-tolerance. Indeed, Treg depletion results in a wide spectrum of autoimmune manifestations,3 whereas mutations of FOXP3 lead to fatal autoimmunity both in mice (scurfy mice) and humans (Immune dysfunction, polyendocrinopathy, enteropathy, X-linked syndrome).1 Further, restoring the T-cell balance in favor of Tregs has allowed the control of autoimmunity in a number of animal rheumatologic models.4